#USA #San Diego #Volta Medical #AF-Xplorer #Heart Rhythm Society

Volta Medical's Groundbreaking AI Innovations at Heart Rhythm Society 2025

Volta Medical, based in Marseille, France, is making significant strides in the realm of cardiac electrophysiology with its advanced artificial intelligence (AI) solutions. The company has announced its participation in the upcoming Heart Rhythm Society (HRS) 2025 conference scheduled for April 24 to 27 in San Diego, California. This annual gathering is a key event for professionals in the field of electrophysiology, where the latest research and technological advancements are shared.

During the conference, Volta Medical will be presenting vital findings from its pioneering clinical trials, with special emphasis on improving operations in atrial fibrillation (AF) treatment. Renowned speakers, including co-founder Dr. Clément Bars and Dr. John Hummel from Ohio State University, will lead sessions focusing on the integration of AI into ablation procedures, showcasing how these technologies can improve patient outcomes.

Highlights of Presentations

Volta Medical's participation will feature a blend of in-person and live online engagements, promoting wide accessibility for attendees. A standout component of their presentation will be the Rhythm Theater session titled “AI-Driven Innovation in AF Ablation Procedures,” moderated by Dr. Vivek Reddy of The Mount Sinai Hospital. The session will also include expertise from panels featuring Dr. Tina Baykaner, Dr. Paul Zei, and Dr. Benjamin D'Souza offering insights into the expanding roles of AI in managing complex AF situations.

The TAILORED-AF Trial Insights

Dr. Clément Bars is set to unveil new findings from the TAILORED-AF clinical trial, a recognized randomized control study demonstrating the effectiveness of Volta's AI-guided approach when compared to traditional pulmonary vein isolation (PVI) methods. This trial focuses on persistent AF patients, who are often underrepresented in clinical practices. The findings will discuss the specific AI applications utilized and how the advanced Volta AF-Xplorer™ technology contributes to these promising outcomes.

RESTART Trial Findings

On the other hand, Dr. John Hummel will shed light on the results from the RESTART trial, which investigates the novel approach of re-ablation for recurrent AF patients who have not achieved optimal outcomes from previous procedures. This research is particularly crucial for a population that remains challenging to treat, with Hummel's report aiming to highlight the efficacy of Volta's AI-driven techniques.

Innovative Technology Showcase

In addition to formal presentations, Volta Medical will also be hosting demonstrations at their booth (#1511), where attendees can interact with the AF-Xplorer system. This advanced AI companion program is designed to identify spatio-temporal dispersed electrograms (EGMs) which significantly aids electrophysiologists in making informed decisions during complex ablation procedures. Its FDA approval and CE Mark certification ensure its reliability and effectiveness in real-world applications.

The Significance of Atrial Fibrillation Awareness

Atrial fibrillation is a widely prevalent arrhythmia affecting approximately 33 million individuals globally. It can lead to serious health complications, including increased stroke risk and heart-related fatalities. Volta Medical not only aims to advance the technology in this field but also works on educating patients about AF through initiatives like the AI for Persistent AF Care program, emphasizing the urgency of addressing this health concern.

Through its innovative technologies and commitment to improving patient management, Volta Medical is positioned as a leader in the cardiac electrophysiology sector. As the Heart Rhythm Society conference approaches, all eyes will be on San Diego to witness the future of cardiac care through the lens of AI-enhanced treatment strategies.